Close
10/02/2016
New mechanism of anti-tumour action for the new drug developped at the UAB
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park, Barcelona Synchrotron Park partner), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.

The study, which has been published in the prestigious journal Clinical Cancer Research, was coordinated by Dr José Miguel Lizcano from the UAB Institute of Neurosciences and Department of Biochemistry and Molecular Biology.

Through the newly identified mechanism, ABTL0812 attacks tumour cells without affecting healthy cells, causing their death by autophagy without activating apoptosis (programmed cell death). It is the first anti-tumour drug to act in this way.

ABTL0812 has recently undergone Clinical Phase I trials in patients with advanced cancer, showing efficacy in several patients (long term stabilization) as well as low toxicity and high tolerability. Clinical Phase II trials are due to start soon in patients with endometrial cancer and lung squamous cell carcinoma.

More news

06/04/2018 Stradivarius Counts On Omnichannel and Aitana Ocaña 21/03/2018 Sun and salt: SENER’s know-how 15/03/2018 Major Upgrade of an ALBA Synchrotron Beamline 01/03/2018 ALBA Synchrotron is as good at humanities as at sciences! 23/02/2018 Catalonia, 2018/19 Top Southern European Region for FDI Strategy 15/02/2018 ICMAB traps sunlight with superabsorbent nanomaterials
11 12 13 14 15 16 17 18 19 20 21